Risk of dementia following androgen deprivation therapy for treatment of prostate cancer
Uro-Oncology
Related content
Uro-Oncology
Androgen deprivation therapy for prostate cancer and risk of dementia
BJU Int.
Robinson D, Garmo H, Van Hemelrijck M, Damber JE, Bratt O, Holmberg L, Wahlund LO, Stattin P, Adolfsson J
doi: 10.1111/bju.14666.
Uro-Oncology
Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis
Prostate Cancer Prostatic Dis.
Cui H, Wang Y, Li F, He G, Jiang Z, Gang X, Wang G
doi: 10.1038/s41391-020-00267-3.
Uro-Oncology
The Risk of New Onset Dementia And/Or Alzheimer's Disease Among Prostate Cancer Patients Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-analysis
J Urol.
Sari Motlagh R, Quhal F, Mori K, Miura N, Aydh A, Laukhtina E, Pradere B, Karakiewicz PI, Enikeev DV, Deuker M, Shariat SF
doi: 10.1097/JU.0000000000001341.
Uro-Oncology
Comparative Effectiveness of Radical Prostatectomy With Adjuvant Radiotherapy Versus Radiotherapy Plus Androgen Deprivation Therapy for Men With Advanced Prostate Cancer
Cancer.
Jang TL, Patel N, Faiena I, Radadia KD, Moore DF, Elsamra SE, Singer EA, Stein MN, Eastham JA, Scardino PT, Lin Y, Kim IY, Lu-Yao GL
doi: 10.1002/cncr.31726.
Uro-Oncology
Supervised exercise therapy compared with no exercise therapy to reverse debilitating effects of androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis
Prostate Cancer Prostatic Dis
Ussing A, Mikkelsen MK, Villumsen BR, Wejlgaard J, Bistrup PE, Birkefoss K, Bandholm T
doi: 10.1038/s41391-021-00450-0
Uro-Oncology
Exercise-induced attenuation of treatment side-effects in newly diagnosed prostate cancer patients beginning androgen deprivation therapy: a randomised controlled trial
BJU Int.
Ndjavera W, Orange ST, O'Doherty AF, Leicht AS, Rochester M, Mills R, Saxton JM
doi: 10.1111/bju.14922.
Uro-Oncology
Androgen Deprivation Therapy in Men With Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2
J Urol.
Klein EA, Li J, Milinovich A, Schold JD, Sharifi N, Kattan MW, Jehi L
doi: 10.1097/JU.0000000000001338.
COMMENTED
Uro-Oncology
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.033.
Uro-Oncology
Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease
Prostate Cancer Prostatic Dis.
Sarkar RR, Patel SH, Parsons JK, Deka R, Kumar A, Einck JP, Mundt AJ, Kader AK, Kane CJ, Riviere P, McKay R, Murphy JD, Rose BS
doi: 10.1038/s41391-020-0241-3.